Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis

Journal article


Publication Details

Author(s): Kürten S, Jackson LJ, Kaye J, Vollmer TL
Journal: Cns Drugs
Publication year: 2018
Volume: 32
Journal issue: 11
Pages range: 1039-1051
ISSN: 1172-7047


Abstract

Growing evidence indicates that B cells play a key role in the pathogenesis of multiple sclerosis (MS). B cells occupy distinct central nervous system (CNS) compartments in MS, including the cerebrospinal fluid and white matter lesions. Also, it is now known that, in addition to entering the CNS, B cells can circulate into the periphery via a functional lymphatic system. Data suggest that the role of B cells in MS mainly involves their in situ activation in demyelinating lesions, leading to altered pro- and anti-inflammatory cytokine secretion, and a highly effective antigen-presenting cell function, resulting in activation of memory or naïve T cells. Clinically, B cell-depleting agents show significant efficacy in MS. In addition, many disease-modifying therapies (DMTs) traditionally understood to target T cells are now known to influence B cell number and function. One of the earliest DMTs to be developed, glatiramer acetate (GA), has been shown to reduce the total frequency of B cells, plasmablasts, and memory B cells. It also appears to promote a shift toward reduced inflammation by increasing anti-inflammatory cytokine release and/or reducing pro-inflammatory cytokine release by B cells. In the authors' opinion, this may be mediated by cross-reactivity of B cell receptors for GA with antigen (possibly myelin basic protein) expressed in the MS lesion. More research is required to further characterize the role of B cells and their bidirectional trafficking in the pathogenesis of MS. This may uncover novel targets for MS treatments and facilitate the development of B cell biomarkers of drug response.


FAU Authors / FAU Editors

Kürten, Stefanie Prof. Dr. med.
Lehrstuhl für Anatomie und Zellbiologie


External institutions with authors

Teva Pharmaceutical Industries Ltd.
University of Colorado System


How to cite

APA:
Kürten, S., Jackson, L.J., Kaye, J., & Vollmer, T.L. (2018). Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis. Cns Drugs, 32(11), 1039-1051. https://dx.doi.org/10.1007/s40263-018-0567-8

MLA:
Kürten, Stefanie, et al. "Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis." Cns Drugs 32.11 (2018): 1039-1051.

BibTeX: 

Last updated on 2019-18-07 at 07:20